Matched-Pair Analysis of Conformal High–Dose-Rate Brachytherapy Boost Versus External-Beam Radiation Therapy Alone for Locally Advanced Prostate Cancer
- 15 August 2000
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (15), 2869-2880
- https://doi.org/10.1200/jco.2000.18.15.2869
Abstract
PURPOSE: We performed a matched-pair analysis to compare our institution’s experience in treating locally advanced prostate cancer with external-beam radiation therapy (EBRT) alone to EBRT in combination with conformal interstitial high–dose-rate (HDR) brachytherapy boosts (EBRT + HDR). MATERIALS AND METHODS: From 1991 to 1998, 161 patients with locally advanced prostate cancer were prospectively treated with EBRT + HDR at William Beaumont Hospital, Royal Oak, Michigan. Patients with any of the following characteristics were eligible for study entry: pretreatment prostate-specific antigen (PSA) level of ≥ 10.0 ng/mL, Gleason score ≥ 7, or clinical stage T2b to T3c. Pelvic EBRT (46.0 Gy) was supplemented with three (1991 through 1995) or two (1995 through 1998) ultrasound-guided transperineal interstitial iridium-192 HDR implants. The brachytherapy dose was escalated from 5.50 to 10.50 Gy per implant. Each of the 161 EBRT + HDR patients was randomly matched with a unique EBRT-alone patient. Patients were matched according to PSA level, Gleason score, T stage, and follow-up duration. The median PSA follow-up was 2.5 years for both EBRT + HDR and EBRT alone. RESULTS: EBRT + HDR patients demonstrated significantly lower PSA nadir levels (median, 0.4 ng/mL) compared with those receiving EBRT alone (median, 1.1 ng/mL). The 5-year biochemical control rates for EBRT + HDR versus EBRT-alone patients were 67% versus 44%, respectively (P < .001). On multivariate analyses, pretreatment PSA, Gleason score, T stage, and the use of EBRT alone were significantly associated with biochemical failure. Those patients in both treatment groups who experienced biochemical failure had a lower 5-year cause-specific survival rate than patients who were biochemically controlled (84% v 100%; P < .001). CONCLUSION: Locally advanced prostate cancer patients treated with EBRT + HDR demonstrate improved biochemical control compared with those who are treated with conventional doses of EBRT alone.Keywords
This publication has 76 references indexed in Scilit:
- Treatment of Prostate Cancer with Goserelin and RadiotherapyNew England Journal of Medicine, 1997
- LONG-TERM RESULTS OF RADICAL RETROPUBIC PROSTATECTOMY IN MEN WITH HIGH GRADE CARCINOMA OF THE PROSTATEJournal of Urology, 1997
- Iridium 192 high-dose-rate brachytherapy ?a useful alternative therapy for localized prostate cancer?World Journal of Urology, 1997
- Radiotherapy for High Grade Clinically Localized Adenocarcinoma of the ProstateJournal of Urology, 1996
- Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate Cancer: The relationship between nadir level and disease-free survivalJournal of Urology, 1996
- Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/mlInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: Preliminary estimates of the therapeutic ratioInternational Journal of Radiation Oncology*Biology*Physics, 1996
- In vitro radiation sensitivity of the lncap prostatic tumor cell lineThe Prostate, 1994
- Patterns of care outcome studies: Results of the national practice in adenocarcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958